CHATTEM, INC D/B/A OPELLA
Registrant: CHATTEM, INC D/B/A OPELLA · 2026 3rd Quarter (July 1 - Sep 30)
$180,000
Total organization expenses, all reported topics
Health Issues
Nonprescription Drug Innovation Act (H.R.9774); dietary supplements; Generally Recognized as Safe (GRAS); Over the Counter Monograph User Fee Act (OMUFA); Generally Recognized as Safe and Effective (GRASE); HR.10336-Dietary Supplement Innovation Act; issues related to Rx to OTC Switch/PDUFA reauthorization.
Lobbyists named: MARYANNE DUNLAP
Congress inferred from reporting year; verify the bill reference in the source.
